Kishi [37] also confirmed that cholinesterase inhibitors could effectively treat mild-to-moderate cognitive impairment in AD patients, and EFNS and APA guidelines recommend acetylcholinesterase inhibitors as a first-line treatment for AD patients with cognitive impairment. This evidence concerns the gene BCHE and Cognitive impairment.